[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,647,165
  • Shares Outstanding, K 113,498
  • Annual Sales, $ 1,397 M
  • Annual Income, $ 316,890 K
  • EBIT $ 746 M
  • EBITDA $ 838 M
  • 60-Month Beta 0.85
  • Price/Sales 8.34
  • Price/Cash Flow 21.51
  • Price/Book 84.80

Options Overview Details

View History
  • Implied Volatility 34.62% (+0.12%)
  • Historical Volatility 57.54%
  • IV Percentile 20%
  • IV Rank 16.22%
  • IV High 52.30% on 10/31/25
  • IV Low 31.19% on 01/20/26
  • Expected Move (DTE 8) 3.38 (3.32%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 381
  • Volume Avg (30-Day) 932
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 22,423
  • Open Int (30-Day) 12,903
  • Expected Range 98.41 to 105.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $2.01
  • Number of Estimates 3
  • High Estimate $2.22
  • Low Estimate $1.86
  • Prior Year $1.63
  • Growth Rate Est. (year over year) +23.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
73.89 +37.76%
on 07/15/26
104.78 -2.85%
on 08/11/26
+25.59 (+33.58%)
since 07/10/26
3-Month
65.60 +55.18%
on 06/02/26
104.78 -2.85%
on 08/11/26
+30.86 (+43.51%)
since 05/12/26
52-Week
61.22 +66.26%
on 12/11/25
104.78 -2.85%
on 08/11/26
+37.75 (+58.95%)
since 08/12/25

Most Recent Stories

More News
The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call

The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call

HALO : 101.79 (-0.81%)
HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance

HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance

HALO : 101.79 (-0.81%)
Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know

Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know

HALO : 101.79 (-0.81%)
1 Profitable Stock to Research Further and 2 We Ignore

1 Profitable Stock to Research Further and 2 We Ignore

MTN : 148.36 (+0.47%)
TTI : 8.74 (-0.91%)
HALO : 101.79 (-0.81%)
Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales

Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales

HALO : 101.79 (-0.81%)
Halozyme Therapeutics: Q2 Earnings Snapshot

Halozyme Therapeutics: Q2 Earnings Snapshot

HALO : 101.79 (-0.81%)
Halozyme's Royalty Engine: Whether Guidance Holds Reveals True Durability of the Model

Barchart Research What to Expect from HALO Earnings HALO Generated August 5, 2026 Current Price $83.59 EPS Estimate $$1.73 Consensus Rating Moderate Buy Average Move 7.08% Halozyme's Royalty Engine: Whether...

HALO : 101.79 (-0.81%)
What To Expect From Halozyme Therapeutics’s (HALO) Q2 Earnings

What To Expect From Halozyme Therapeutics’s (HALO) Q2 Earnings

HALO : 101.79 (-0.81%)
3 Growth Stocks Set to Flourish

3 Growth Stocks Set to Flourish

HAPN : 19.49 (+1.35%)
RKLB : 81.17 (+1.45%)
HALO : 101.79 (-0.81%)
1 Cash-Producing Stock on Our Watchlist and 2 We Ignore

1 Cash-Producing Stock on Our Watchlist and 2 We Ignore

EE : 35.75 (+1.10%)
VNT : 33.42 (-1.94%)
HALO : 101.79 (-0.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company...

See More

Key Turning Points

3rd Resistance Point 104.87
2nd Resistance Point 103.72
1st Resistance Point 102.76
Last Price 101.79
1st Support Level 100.65
2nd Support Level 99.50
3rd Support Level 98.54

See More

52-Week High 104.78
Last Price 101.79
Fibonacci 61.8% 88.14
Fibonacci 50% 83.00
Fibonacci 38.2% 77.86
52-Week Low 61.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.